Insider Selling: Artivion (NYSE:AORT) CAO Sells 4,572 Shares of Stock

by · The Cerbat Gem

Artivion, Inc. (NYSE:AORT – Get Free Report) CAO Amy Horton sold 4,572 shares of Artivion stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $44.42, for a total transaction of $203,088.24. Following the sale, the chief accounting officer owned 130,058 shares in the company, valued at approximately $5,777,176.36. The trade was a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Amy Horton also recently made the following trade(s):

  • On Monday, November 17th, Amy Horton sold 6,000 shares of Artivion stock. The stock was sold at an average price of $45.73, for a total transaction of $274,380.00.
  • On Thursday, November 13th, Amy Horton sold 3,482 shares of Artivion stock. The shares were sold at an average price of $45.86, for a total value of $159,684.52.
  • On Monday, November 10th, Amy Horton sold 1,789 shares of Artivion stock. The stock was sold at an average price of $44.62, for a total value of $79,825.18.

Artivion Price Performance

Artivion stock traded down $0.75 during midday trading on Tuesday, reaching $43.32. 337,020 shares of the stock traded hands, compared to its average volume of 428,999. The stock has a market cap of $2.05 billion, a P/E ratio of -180.50 and a beta of 1.60. The stock’s fifty day moving average is $44.07 and its 200-day moving average is $38.34. The company has a quick ratio of 2.88, a current ratio of 3.93 and a debt-to-equity ratio of 0.50. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.04.

Artivion (NYSE:AORT – Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. The firm had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. Artivion had a negative net margin of 2.16% and a positive return on equity of 5.98%. The firm’s revenue for the quarter was up 18.9% on a year-over-year basis. As a group, equities research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Investors Weigh In On Artivion

Institutional investors have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd lifted its position in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after buying an additional 519 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Artivion during the 3rd quarter worth approximately $27,000. Smartleaf Asset Management LLC lifted its position in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after acquiring an additional 538 shares during the last quarter. State of Wyoming acquired a new stake in Artivion in the third quarter valued at approximately $80,000. Finally, Quadrant Capital Group LLC acquired a new position in shares of Artivion during the third quarter worth $92,000. Institutional investors own 86.37% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on AORT. LADENBURG THALM/SH SH lowered shares of Artivion from a “buy” rating to a “neutral” rating and boosted their target price for the company from $32.00 to $38.80 in a research note on Wednesday, August 13th. Citizens Jmp upped their target price on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Citigroup reaffirmed an “outperform” rating on shares of Artivion in a research report on Friday, October 10th. Needham & Company LLC increased their price objective on Artivion from $50.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Artivion currently has a consensus rating of “Moderate Buy” and an average target price of $49.11.

View Our Latest Stock Analysis on AORT

Artivion Company Profile

(Get Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Read More